DOI: http://dx.doi.org/10.18203/2349-3933.ijam20174673

A prospective and open label study of use of cilnidipine and chlorthalidone fixed dose combination in Indian hypertensive patients, intolerant or uncontrolled on amlodipine and hydrochlorothiazide combination

Suresh V. Sagarad, Hari Prasad S.

Abstract


Background: Primary aim of this study was to evaluate the antihypertensive efficacy of the Cilnidipine and Chlorthalidone fixed dose combination in Indian hypertensive patients who are not controlled on traditionally used amlodipine and hydrochlorothiazide combination and also to evaluate the safety of this combination.

Methods: A total of 70 eligible patients were enrolled in this prospective, open label study. The patients were given cilnidipine (10 mg) and chlorthalidone (12.5 mg) who had not achieved target blood pressure (140/90 mmHg) despite on amlodipine (5 mg) and hydrochlorothiazide (12.5mg) combination or are intolerant to the medication. The assessment was done at the end of 4 weeks and 8 weeks.

Results: There were significant falls in the SBP (5.43±2.45 mmHg, P<0.05), and DBP (4.11±2.35 mmHg, P<0.05) at the end of 4 weeks as compared to those at the baseline. The trend was sustained at 8 weeks. No further significant fall in the SBP and DBP were noted after 4 weeks (5.43±2.45 and 5.22±2.38 mmHg at 4 weeks vs 4.11±2.35 and 4.01±2.23 mmHg at 8 weeks P=NS). The SBP target (140 mmHg) was achieved in 25 patients (35.71%). The DBP target (90 mmHg) was achieved in 18 patients (25.71%). The combined SBP and DBP target was achieved in 12 patients (17.14%). A similar fall in the SBP was observed in the subgroups which were analysed.

Conclusions: The hypertensive patients who do not achieve the target blood pressures on amlodipine and hydrochlorothiazide can be switched to the cilnidipine and chlorthalidone combination. The combination is effective and well tolerated.


Keywords


Amlodipine, Cilnidipine, Chlorthalidone, Hypertension, Hydrochlorothiazide

Full Text:

PDF

References


Scholze J, Bida M, Hansen A, Juncken D, Ragoonwala B, Ritz A, et al. Initiation of hypertension treatment with a fixed dose combination or its monocomponents-Does it really matter ? Int J Clinical Pract. 2006;60:265-74.

Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present and future. Am J Cardiol. 2007;100:3J-9J.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC Report. JAMA. 2003;289:2560-72.

European Society of Hypertension. European Society of Cardiology Guidelines for the management of arterial hypertension. J hypertens. 2003;21:1011-53.

National Institute for Health and Clinical Excellence. Clinical management of primary hypertension in adults. NICE clinical guidelines CG 127. London: National Institute for Health and Clinical Excellence; 2011.

Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka m, McKay DW, Hackam DG. The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian J of Cardiol. 2012;28: 270-87.

Drugs for the HEART: Lionel Opie and Bernard J Gersch. 7th Edition; 2009.

Uneyama H, Uchida H, Konda T, Yashimoto R. Cilinidipine: Preclinical and clinical evaluation. Cardiovasc Drug Review. 1999;17:341-57.

Takahara A. Dual L/N Type Ca2+ Channel Blocker: Cilnidipine as a New Type of Antihypertensive Drug. Antihypertensve Drugs, Prof Hossein Babaei (Ed), In Tech; 2012 available from: http://www.intechopen.com/books/antihypertensive-drugs/dual-l-n-type-ca2-channel-blocker-cilnidipine.

Liu GZ, Wang W, Yaho CH. Hypertension prevention guide (2009 grass-roots version). Chines J Hypertens. 2010;18:11-30.

Chen YY, Sun NL, Zhao XL. The efficacy and safety study of domestic cilnidipine treatment of mild to moderate hypertension. Chin J Clin Pharmacol. 2003;19:334-7.

Ma SP, Guo XM, Li CaiRu. The efficacy and safety of cilnidipine treatment of mild to moderate hypertension. Chin J Drugs Cli Rem. 2004;23:873-5.

Huang GZ, Wu ZG, Lu GP. Domestic cilnidipine treatment of mild to moderate essential hypertension. Chin J Hypertens. 2007;15:124027.

Zhao XL, Zhou YM, Li Jie. The efficacy and safety of cilnidipine treatment of mildto moderate hypertension. Chinese J of New Drugs. 2008;17: 157-9.

Zhou XL. The efficient observation of cilnidipine treatment of mild to moderate hypertension. Chin J Clin Rational Drug Use. 2011;4:49-50.

Guo-liang X, Hui X, Hai-di W, Ling Q. A meta analysis of the efficacy of cilnidipine in Chinese patients with mild to moderate essential hypertension, AJPP. 2012;6:2393-9.

Malleshappa P. Cilnidipine effectively reduces low-grade albuminuria in hypertensive chronic kidney disease patients. Diálisis y Trasplante. 2013;34(1):2-6.

Sagarad SV, Chaitanya Kumar S, Ramakrishna MR, Sudha Biradar-Kerure, Javali NS, Reddy SS, Surpur RR, Patil V. A prospective and open label study to assess antihypertensive efficacy and safety of cilnidipine-A novel dual acting calcium channel blocker in Indian hypertensive patients. International J of Universal Pharmacy and Bio Sci. 2013;2(3);11-7.

Prasad RS. Replacement of amlodipine with cilnidipine and assessment of pedal edema along with blood pressure control. Sch J App Sci. 2015; 3(4A):168-82.

Shetty R, Vivek G, Naha K, Tumkur A, Raj A, Bairy KL. Excellent tolerance of cilnidipine in hypertensives with amlodipine induced edema. N Am J Mes Sci. 2013;5(1):47-50.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.

Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lissinopril. JAMA. 2005;293:1595-1608.

Psaty BM, Lumley T, Furberg CD, Marco Pahlor GS, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first line agents: a network meta-analysis. JAMA. 2003;289:2534-44.

Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative group. JAMA. 1979;242:2562-71.

The Multiple Risk Factor Intervention Trial Research Group (MRFIT). Mortality rates after 10.5 years for hypertensive participants in the Multiple Risk Factors Intervention Trial. Circulation. 1990;82:1616-28.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.

Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PA, et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713-24.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC Report. JAMA. 2003;289:2560-72.

Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:4-9.

Earnst ME, Carter BL, Goerdt CJ. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-8.

Lund BC, Ernst MC. The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans. J Clin Hypertens (Greenwich). 2012;14:623-9.

European Society of Hypertension. European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.

Zidek W. Hochdruckleitlinien iiberabeitet. Was ist Praxis relevant? MMW Fortschr Med. 2004;1-2:16/37-8/17.

Osterloh I. The safety of amlodipine. Am Heart J. 1989;118:1114-20.

Jayanthi R, Kalifa AM, Archana BM, Jayachandran S, Varghesse F. Prevalence and severity of amlodipine induced gingival overgrowth. Internat J Contempt Medic Res. 2017;4(2):377-9.

Sumana K, Suryanarayana KM, Selvan C, Nagaraj HK. A case of primary amenorrhea presenting with hypokalemic paresis and hypertension. International J Contempt Medic Res. 2017;4(4):970-2.

Babu AK. Assessment of efficacy of amlodipine with cilnidipine in hypertensive patients: a comparative study. Internat J Contempt Medic Res. 2017;4(4):956-8.